Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.71 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941570 | 1.00 | CTSK (0.71) | CTSKCTSSCTSLCTSBCA12 | |
| SCHEMBL4043486 | 0.89 | CTSK (0.74) | CTSKCTSSCCR1 | |
| SCHEMBL5941969 | 0.89 | CTSK (0.74) | CTSKCTSSCCR1 | |
| SCHEMBL5941972 | 0.89 | CTSK (0.74) | CTSKCTSSCCR1 | |
| SCHEMBL13909111 | 0.87 | CTSK (0.72) | CTSKCTSSCTSLCA12CA1 | |
| SCHEMBL4219111 | 0.85 | CTSK (0.78) | CTSKCTSSCTSLCCR1 | |
| SCHEMBL5941619 | 0.85 | CTSK (0.78) | CTSKCTSSCTSLCCR1 | |
| SCHEMBL4219105 | 0.85 | CTSK (0.78) | CTSKCTSSCTSLCCR1 | |
| SCHEMBL4038504 | 0.85 | CTSK (0.78) | CTSKCTSSCTSLCCR1 | |
| SCHEMBL5941785 | 0.84 | CTSK (0.80) | CTSKCTSSCTSLCTSBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CTSL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.